
Under fire, AstraZeneca hustles out a primary cut of the numbers for its Covid-19 vaccine supporting positive efficacy
After spending the last 48 hours in a pressure cooker of widespread criticism, AstraZeneca has updated its data on its controversial Covid-19 vaccine.
The pharma giant announced Wednesday evening that their vaccine was 76% effective in the primary analysis, a small slip on overall efficacy from its first cut of the data. There was 100% efficacy in preventing severe disease and hospitalization. The slight revision still bears up well in comparison with the 72% efficacy rate cited by J&J for its vaccine, leaving AstraZeneca in a solid position to win an emergency authorization from the FDA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.